Patents by Inventor Stephen M.G. Gottschalk

Stephen M.G. Gottschalk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VASCULAR-TARGETED T-CELL THERAPY
    Publication number: 20160015750
    Abstract: Embodiments of the invention provide for cell therapy for cancers having a TEM1 or TEM8 antigen. Certain embodiments provide for cell therapy that targets tumor vasculature, including the tumor vascular bed, for example. In specific embodiments, TEM1- and/or TEM8-specific chimeric antigen receptors are employed.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 21, 2016
    Inventors: Stephen M. G. Gottschalk, LaTerrica C. Williams, Tiara T. Byrd, Nabil M. Ahmed, Xiao-Tong Song
  • ONCOLYTIC VIRUS
    Publication number: 20160000842
    Abstract: Embodiments of the present disclosure concern oncolytic viruses, such as vaccinia virus, for example, for the treatment of cancer, wherein the viruses encode an engager molecule having an activation domain that recognizes a cell molecule, such as CD3, for example, on T cells and an antigen recognition domain that recognizes a tumor antigen, such as EphA2, HER2, GD2, or Glypican-3, for example. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example. Methods of treating cancer using one or more of the compositions are encompassed in the disclosure.
    Type: Application
    Filed: March 5, 2014
    Publication date: January 7, 2016
    Inventors: Xiao-Tong Song, Stephen M. G. Gottschalk, Feng Yu
  • EBV-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF LOCOREGIONAL NASOPHARYNGEAL CARCINOMA (NPC)
    Publication number: 20140086888
    Abstract: The present invention concerns methods and compositions for treatment of locoregional nasopharyngeal carcinoma utilizing EBV-specific T cells. In specific embodiments, locoregional solid tumors are treated with cytotoxic T lymphocytes specific for at least one EBV antigen, such as LMP2, LMP1, and/or EBNA1, for example.
    Type: Application
    Filed: September 1, 2011
    Publication date: March 27, 2014
    Inventors: Helen E. Heslop, Karin Straathof, Stephen M.G. Gottschalk, Cliona M. Rooney, Chrystal U. Louis, Malcolm Brenner
  • IMMUNOTHERAPY OF CANCER USING GENETICALLY ENGINEERED GD2-SPECIFIC T CELLS
    Publication number: 20140004132
    Abstract: The present invention concerns immunotherapy for cancers having cells that comprise the ganglioside GD2 antigen. In specific embodiment, T cells having a chimeric receptor that targets GD2 is employed. In particular cases, the chimeric receptor comprises antibody, cytoplasmic signaling domain from the T cell receptor, and/or costimulatory molecule(s).
    Type: Application
    Filed: September 8, 2011
    Publication date: January 2, 2014
    Inventors: Malcolm Brenner, Gianpietro Dotti, Nabil Ahmed, Claudia Rossig, Stephen M.G. Gottschalk, Zakaria Grada
  • CHIMERIC CD27 RECEPTORS FOR REDIRECTING T CELLS TO CD70-POSITIVE MALIGNANCIES
    Publication number: 20130323214
    Abstract: The present invention concerns methods and compositions related to T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. In aspects of the invention, T cells that are CD70-specific are employed. In particular aspects, there are T cells expressing a novel molecule that comprises the full-length CD70 receptor (CD27) fused to the zeta signaling domain of the T-cell receptor complex. Such T cells recognized CD70-positive tumor cells and have cytolytic activity against CD70-positive cancer cells.
    Type: Application
    Filed: October 27, 2011
    Publication date: December 5, 2013
    Inventors: Stephen M.G. Gottschalk, Donald R. Shaffer, David M. Spencer